Option Care Health, Inc. $OPCH Shares Bought by Millennium Management LLC

Key Points

• Millennium Management LLC increased its holdings in Option Care Health by 5.9%, owning approximately 0.84% of the company, valued at $48.3 million at the end of the first quarter.
• Directors Harry M. Jansen Kraemer, Jr. and Timothy P. Sullivan significantly increased their stock positions, with Kraemer acquiring 36,000 shares and Sullivan purchasing 20,000 shares.
• Option Care Health reported a 15.4% year-over-year revenue increase for the quarter, achieving $1.42 billion, and provided FY 2025 earnings guidance of $1.650-1.720 EPS.

Millennium Management LLC lifted its stake in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 5.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,382,110 shares of the company's stock after purchasing an additional 77,495 shares during the period. Millennium Management LLC owned about 0.84% of Option Care Health worth $48,305,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Fuller & Thaler Asset Management Inc. lifted its holdings in Option Care Health by 30.8% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 4,204,481 shares of the company's stock worth $146,947,000 after buying an additional 989,048 shares during the last quarter. Durable Capital Partners LP purchased a new stake in Option Care Health during the 1st quarter worth about $122,905,000. Charles Schwab Investment Management Inc. lifted its holdings in Option Care Health by 4.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,609,705 shares of the company's stock worth $91,209,000 after buying an additional 99,574 shares during the last quarter. Nuveen LLC purchased a new stake in Option Care Health during the 1st quarter worth about $70,965,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in Option Care Health by 8.8% during the 1st quarter. The Manufacturers Life Insurance Company now owns 1,651,489 shares of the company's stock worth $57,720,000 after buying an additional 133,497 shares during the last quarter. 98.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on OPCH shares. JMP Securities lifted their price target on Option Care Health from $36.00 to $38.00 and gave the stock a "market outperform" rating in a report on Thursday, July 31st. Citigroup reaffirmed an "outperform" rating on shares of Option Care Health in a report on Thursday, July 31st. Finally, Barrington Research reaffirmed an "outperform" rating and set a $38.00 price target on shares of Option Care Health in a report on Thursday, July 10th. Eight analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Option Care Health has a consensus rating of "Moderate Buy" and an average target price of $35.75.

Insider Transactions at Option Care Health

In other news, Director Harry M. Jansen Kraemer, Jr. acquired 36,000 shares of the firm's stock in a transaction on Wednesday, August 20th. The stock was bought at an average cost of $27.15 per share, with a total value of $977,400.00. Following the transaction, the director directly owned 375,390 shares in the company, valued at approximately $10,191,838.50. This represents a 10.61% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Timothy P. Sullivan acquired 20,000 shares of the firm's stock in a transaction on Thursday, August 21st. The stock was purchased at an average cost of $27.51 per share, with a total value of $550,200.00. Following the completion of the transaction, the director owned 49,229 shares in the company, valued at $1,354,289.79. The trade was a 68.43% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 59,411 shares of company stock worth $1,627,576 in the last ninety days. Insiders own 0.64% of the company's stock.

Option Care Health Price Performance

Shares of NASDAQ:OPCH traded down $0.89 during trading on Friday, hitting $28.48. 1,626,043 shares of the stock were exchanged, compared to its average volume of 1,864,932. Option Care Health, Inc. has a 12-month low of $21.39 and a 12-month high of $35.53. The company has a current ratio of 1.52, a quick ratio of 1.00 and a debt-to-equity ratio of 0.81. The company has a fifty day moving average price of $29.09 and a two-hundred day moving average price of $31.42. The company has a market cap of $4.62 billion, a PE ratio of 22.78, a P/E/G ratio of 1.73 and a beta of 0.83.

Option Care Health (NASDAQ:OPCH - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.40 by $0.01. Option Care Health had a return on equity of 17.53% and a net margin of 3.93%.The firm had revenue of $1.42 billion for the quarter, compared to analyst estimates of $1.35 billion. During the same quarter in the prior year, the company earned $0.30 EPS. Option Care Health's revenue was up 15.4% on a year-over-year basis. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. On average, analysts forecast that Option Care Health, Inc. will post 1.22 EPS for the current year.

Option Care Health Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.